Disease: Myelodysplastic myeloproliferative disease
- <em>BRAF</em> mutation in myeloid neoplasm: incidences and clinical outcomes
- A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related
- A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC
- An Autopsy Case of Severe COVID-19 Pneumonia Complicated by Intrapulmonary Thrombosis in Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
- Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies
- Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing
- Assessment of a novel NRAS in-frame tandem duplication causing a myelodysplastic/myeloproliferative neoplasm
- Atypical chronic myeloid leukemia found in a patient with eosinophilia for six years: a case report
- Atypical CML: diagnosis and treatment
- BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
- Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup
- Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies
- Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry
- Cabot rings in a cat with myeloproliferative disease
- Cabot rings in chronic myelomonocytic leukemia
- Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic
- Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study
- Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease
- Chronic Myelomonocytic Leukemia-Associated Immune Thrombocytopenic Purpura: A Report of a Rare Case and a Review of Literature
- Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
- Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management
- Clinical Characteristics and Diagnosis of Nonaccelerating MDS/MPN-U Patient with Granulocyte Dysplasia
- Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia
- Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia
- Clinical study of the efficacies of ruxolitinib plus low-dose PTCY for acute GVHD prevention after haploidentical transplantation in malignant hematological diseases
- Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022
- Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study
- Concurrent chronic myelomonocytic leukemia and gastric carcinoma: a case report and literature review
- CSF3R mutated myeloid neoplasms: Beyond chronic neutrophilic leukemia
- Current state and future prospects of CAR T-cell therapy for myeloid malignancies
- Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogenetique Hematologique (GFCH)
- Deciphering Acute Myeloid Leukemia Associated Transcription Factors in Human Primary CD34+ Hematopoietic Stem/Progenitor Cells
- Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia
- Decreased spermatogonial numbers in boys with severe haematological diseases
- Detection of dysplasia in peripheral blood: Proposal of an algorithm to detect myelodysplastic syndromes and chronic myelomonocytic leukemias on a high-speed technical platform using the Sysmex XN analyser
- Discrepant low von Willebrand factor activity results on the ACL TOP analyzer are frequent in unselected patients with myeloproliferative neoplasms and show no correlation with high-molecular-weight multimer loss or bleeding phenotype
- Discrepant low VWF:GPIbR results on the ACL TOP analyser are frequent in unselected patients with myeloproliferative neoplasms, and show no correlation with high molecular weight multimer loss or bleeding phenotype
- Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML
- EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
- Enhanced Survival of Chronic Myelomonocytic Leukemia-Dysplastic over Proliferative Subtype after Allogeneic Hematopoietic Cell Transplant: A Tertiary Center Experience and Literature Review
- Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations
- Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
- Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms
- First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis
- Germline <em>CSF3R</em> Variant in Chronic Myelomonocytic Leukemia: Linking Genetic Predisposition to Uncommon Hemorrhagic Symptoms
- Germline bi-allelic <em>SH2B3/LNK</em> alteration predisposes to a neonatal juvenile myelomonocytic leukemia-like disorder
- Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders
- Granulomatous dermatitis in the context of chronic myelomonocytic leukemia: More than just reactive infiltrates. An illustrative case report with literature review
- Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide
- Hematological Neoplasms with Eosinophilia
- Infantile Disseminated Bacille Calmette-Guerin Disease with Hemophagocytosis and Mimicking Juvenile Myelomonocytic Leukemia: A Case Report with Concise Literature Review
- Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia
- Integrated Clinical Genotype-phenotype Characteristics of STAT3-mutated Myeloid Neoplasms
- IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
- JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome
- KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia
- LNK/<em>SH2B3</em> as a novel driver in juvenile myelomonocytic leukemia
- Long-term remission of infantile Takayasu arteritis associated with germline CBL syndrome after allogeneic hematopoietic stem cell transplantation: A case report and literature review
- Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee
- Myelodysplastic neoplasms and chronic myelomonocytic leukaemias
- Myeloid sarcoma in JAK2-positive myelodysplastic neoplasms with fibrosis: a case report and literature review
- Myeloid sarcoma: Experience from a tertiary care center in southern India - A series of eight unusual cases
- NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy
- Noonan Syndrome-related Myeloproliferative Disorder Occurring in the Neonatal Period: Case Report and Literature Review
- Obliteration of liver sinusoids through platelet aggregates associated to extramedullary haematopoiesis in myeloid neoplasms
- Observation and Management of Juvenile Myelomonocytic Leukemia and Noonan Syndrome-Associated Myeloproliferative Disorder: A Real-World Experience
- Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
- Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
- Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience
- Overlapping Stromal Alterations in Myeloid and Lymphoid Neoplasms
- Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review
- Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents
- Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes
- Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes
- Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms
- Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study
- Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis
- Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia
- Racial, Ethnic and Socioeconomic Diversity and Outcomes of Patients with Graft-versus-Host Disease: A CIBMTR Analysis
- Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
- Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
- Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression
- Recurrent Aortic Thromboembolism Associated With <em>TET2</em> Mutation in Chronic Myelomonocytic Leukemia
- Report on hematopoietic cell transplantations performed in 2018/2019 focusing on the trends of selection of stem cell sources in the Asia-Pacific region: APBMT Activity Survey
- Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies
- SH2B3 alterations in a novel genetic condition, juvenile myelomonocytic leukemia, and myeloproliferative neoplasia
- Should oligomonocytic CMML be classified as an independent disease entity?
- STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia
- Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia
- Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia
- The role of flow cytometry in the classification of myeloid disorders
- Therapeutic efficacy of RAS inhibitor trametinib using a juvenile myelomonocytic leukemia patient-derived xenograft model
- Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
- Too many white cells-TAM, JMML, or something else?
- Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay
- Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study
- Validation of a novel algorithm with a high specificity in ruling out MDS
- Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification
- Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with <em>RUNX1</em> mutation
- When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms